SAUDI-SPORTS-FOR-ALL
11.2.2024 22:19:26 CET | Business Wire | Press release
More than 20,000 participants from 125 countries, including a record 60% Saudi nationals, took part in the third edition of the Riyadh Marathon on February 10 – an increase of more than 33%, with 15,000 runners in 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240211783273/en/
Riyadh Marathon Presented by SAB (Graphic: AETOSWire)
For the first time, the start and finish line, and the accompanying Marathon Village, were located next to Kingdom Arena and Boulevard World. From there, competitors of all ages and abilities could enjoy one of four races – the full marathon (42.2km), half marathon (21.1km), 10km, and 4km family run. Across the four races, there were more than 20,000 participants, with a significant increase in female runners, exceeding 7,200. In total, 64% were males, with 36% female.
The top three elite male marathon runners were Kigen Wilfred Kirwa of Kenya, Tilahun Abe Gashahun of Ethiopia, and El Ghouz Anouar of Morocco, who were awarded US$30,000, US$20,000, and US$10,000 respectively. The top three female elite marathon runners, receiving the same amounts, were Badane Bedatu Hirpa, Desta Nigist Muluneh, and Jebesa Zenebu Fikadu, all from Ethiopia. Prizes for elite runners in the half marathon started at US$5,000 for first place.
SFA President HRH Prince Khaled bin Alwaleed bin Talal Al Saud said: “In line with the mandate of the Saudi Vision 2030 initiative, events such as this are building a healthier, happier population. And with increasing numbers of participants from abroad, we are raising Saudi Arabia’s profile as a sporting nation.”
SFA Managing Director Shaima Saleh Al-Husseini said: “The remarkable figure of 36% female participation underscores our concerted efforts to empower women through sports, and helps to realize the ambitious goals of Saudi Vision 2030. This milestone achievement heralds a brighter, healthier future.”
Organized by the Saudi Sports for All Federation (SFA), in collaboration with the Ministry of Sport, the Saudi Arabian Olympic & Paralympic Committee, and the Saudi Arabian Athletic Federation, the event sponsors included Saudi Awwal Bank, and headline sponsors ROSHN, PepsiCo, ASICS, Twauniya, Genesis, and Al Arabiya, with a total of US$197,000 in cash prizes awarded to winners. The event was also sponsored by JPMorgan, Hisamitsu, Activia, L’Oréal, GSK, CALO, Kudu, Delta Sports, and MDLBeast.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240211783273/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom